|Bid||2.4400 x 2900|
|Ask||2.5900 x 3000|
|Day's Range||2.4700 - 2.6200|
|52 Week Range||1.6200 - 3.8400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Exicure, Inc. today announced the closing of its previously announced underwritten public offering of its common stock to the public.
Exicure, Inc. today announced the pricing of the previously announced underwritten public offering of 10,000,000 shares of its common stock.
Exicure announced Friedreich’s Ataxia (FA) as the therapeutic indication for the company’s first neurology development program and expansion of SAB.
Shares of Exicure Inc. gained 6% in premarket trading after it said that it will start enrolling patients in a Phase 2 trial for the biotech's experimental immuno-oncology drug. Exicure last month announced a deal with Allergan in which the companies will develop treatments for hair loss disorders. Exicure stock is down 15% year-to-date, while the S&P 500 is up about 25%.
Exicure announced an update from its Phase 1b/2 trial with AST-008 in patients with solid tumors.
It’s hard for the little guys to get noticed sometimes, but often, it’s the little guys that are worth watching. Naturally, this applies to investing, too.Much has been said already about the record-breaking year for the S&P 500. As we reached the final month of the decade, after such a sustained rally, it is getting harder and harder to find true bargains. The top analysts, though, know that further down the market cap ladder, unseen by the casual observer, is where some of the true gems reside, the ones from which investors stand to reap substantial rewards.So, we took out our virtual bargain detector, opened TipRanks’ Stock Screener and looked for 3 stocks with smaller market caps poised for growth, specifically ones the analysts think are set for gains in the months ahead. Let’s take a closer look.International Money Express (IMXI)Remittances are making an increasingly large impact on the economies of many countries, playing a part in their economic growth, and in people’s livelihoods. Overall global remittance is expected to grow 3.7% to $715 billion in 2019. This includes $549 billion to developing nations.One company hoping to get a slice of the growing industry is International Money Express. The Miami based company provides remittance services for select Latin American markets, with strongholds in the two biggest markets - it is the market leader in Guatemala, and the second largest provider in Mexico.Additionally, IMXI has set its sights on new territories, both in Latin America and Africa, as well as expanding in the US and Canada. The company favors a differentiated agent acquisition strategy of handpicking agents with which the local migrant population has a cultural or linguistic affinity over increasing the number of agent locations.Cowen’s George Mihalos thinks the game plan is working well. The 5-star analyst noted, “We believe IMXI deserves a premium valuation relative to its money remittance peers given its superior growth profile and differentiated business model [..] We see IMXI leveraging its differentiated agent strategy to further capture market share in the Latin American remittance corridor, driving sustainable low-mid teens revenue growth. With the shares trading at a discount to slower growing peers such as WU, we see an opportunity for multiple expansion near term.”To this end, Mihalos initiated coverage on IMX stock with an Outperform rating, along with a price target of $17. This conveys the 5-star analyst’s confidence in IMXI’s ability to climb 32% higher in the next 12 months. (To watch Mihalos’ track record, click here)Where does the rest of the Street side on this digital payments platform? It appears mostly bullish, as TipRanks analytics demonstrate IMXI as a Strong Buy. Out of 5 analysts tracked by TipRanks in the last 3 months, 4 are bullish on the stock while 1 remains sidelined. With a return potential of nearly 36%, the stock’s consensus target price stands at $17.50 (See IMXI stock analysis on TipRanks)Exicure (XCUR)With a market cap of $219.6 million, Exicure is the smallest company on our list. The micro-cap biotech focuses on developing drugs for neurology, oncology, and dermatology.Exicure’s unique selling point (USP) is its proprietary spherical nucleic acid (SNA) technology, which can better the delivery and efficiency of current nucleic acid-based therapies. The company is expected to announce its first SNA based neurology candidate before year’s end, and it has indicated it will be a rare indication for which there are few available therapies. In addition, Exicure also recently announced an agreement with Allergan to develop treatments for hair disorders, also based on Exicure’s SNA technology.The pioneering biotech has excited Guggenheim’s Yatin Suneja, who wrote, “We expect XCUR’s SNA platform to attract interest from biopharma companies. We believe that nucleic acid therapeutics are a growing class of products, and the highly adaptive SNA technology could potentially improve the delivery and efficiency of multiple compounds. Therefore, we expect strong interest (as highlighted by a recent collaboration with Allergan) from various biopharma players in partnering with XCUR to leverage this technology.”As a result, Suneja thinks the stock, currently at $2.89, will soon be worth $9.00 a share, and recommends buying it. We are talking about over 200% upside here. (To watch Suneja’s track record, click here)Suneja’s bullish call resonates with the Street. Although only 3 analysts have weighed in with a view on Exicure over the last 3 months, all have rated the biotech pioneer as a Buy, making the Street consensus a Strong Buy. The average target stands at $7.33, below Suneja’s target, but still providing ample upside of 154%. (See Exicure stock analysis on TipRanks)Teladoc (TDOC)The advent of the smartphone has changed the way we interact with the world in every possible way, from shopping, to how we get around, to how we consume culture, amongst many other novelties. One industry going through a smart technological transformation right now is the health industry, with the rise of the telehealth space disrupting traditional doctor-patient conventions.RBC’s Sean Dodge thinks Teledoc is ‘virtually unstoppable,’ noting, “Virtual health is going mainstream. Awareness and comfort with the technology is reaching a tipping point and the breadth of potential use-cases is expanding rapidly. There are more examples of this surfacing across healthcare every day. We are also seeing increasing evidence Virtual First benefit design is beginning to take hold, which adds even more momentum to our outlook. While the rising tide will lift all boats, we believe Teladoc is the best positioned to capitalize on this. It's superior consumer engagement platform, breadth of offerings/clinical capabilities and global reach are all important and durable competitive differentiators. The combination of new member adds, cross-selling and ramping utilization should continue to drive 25%+ organic revenue growth for the next 3+ years..”On the back of the glowing assessment, Dodge initiated coverage on Teladoc stock, with an Outperform rating. The analyst suggests that if everything goes as planned, TDOC will be a $100 stock in the next 12 months, implying nearly 28% return. (To watch Dodge’s track record, click here)To find other good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Shares of Exicure are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan to develop treatments for hair loss disorders. Exicure will receive an upfront payment of $25 million. In addition, it can receive milestone payments up to $97.5 million per R&D program and up to $265 million per commercial program. Allergan's portfolio has long been known for top-selling beauty brands like the medical fillers Botox and Juvéderm. Its $63 billion acquisition by AbbVie is expected to close early next year. Exicure stock is down 30.51% year-to-date, while the S&P 500 has risen 23%.
Exicure, Inc., (XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Exicure, Inc. have entered into a global collaboration agreement to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Under the terms of the agreement, Allergan will receive exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders.
Crain’s “40 Under 40” recognizes individuals who are reinventing what it means to do business in Chicago through financial impact and community leadership. Dr. Giljohann, along with the other honorees, will be profiled in the November 18 issues of Crain’s Chicago Business. “It is truly an honor to be recognized for my work at Exicure, which has always been driven by my personal goal of positively impacting patients by creating revolutionary new medicines,” says Giljohann.
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, today reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress.
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced today that its chief financial officer, David Snyder, will give a company update on Tuesday, October 22, 2019 at 11:00am PT at the 2019 BIO Investor Forum in San Francisco.
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced that its chief executive officer, Dr. David Giljohann, presented clinical data from the company’s drug candidate XCUR17 in psoriasis today during the Oligonucleotides Clinical Studies session at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Munich.
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis. The presentation, titled “Clinical Results from XCUR17, a Topically Applied Antisense Spherical Nucleic Acid in Patients with Psoriasis,” will take place on Wednesday, October 16, 2019 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich. The presentation will occur during Session IX, which is focused on Oligonucleotide Clinical Studies.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system. In Exicure’s foundational study, 7mg of radio-labeled SNAs were injected intrathecally into cynomolgus monkeys. The biodistribution of the SNAs was followed for 14 days by PET/CT scans.